.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,596,316

« Back to Dashboard

Claims for Patent: 6,596,316

Title: Preparation of microparticles having a selected release profile
Abstract:An improved method for preparing microparticles that exhibit controlled release of an effective amount of an active agent over an extended period of time. More particularly, a method is provided for preparing microparticles having a selected release profile for release of active agent contained in the microparticles. By adjusting the degree of drying that is performed during the preparation of the microparticles, the release profile can be controlled. By performing no intermediate drying, an initial burst and a substantially linear release profile is achieved. By performing substantially complete intermediate drying, an initial lag phase and a substantially sigmoidal release profile is achieved.
Inventor(s): Lyons; Shawn L. (Cincinnati, OH), Ramstack; J. Michael (Lebanon, OH), Wright; Steven G. (Madeira, OH)
Assignee: Alkermes Controlled Therapeutics, Inc. II (Cambridge, MA)
Application Number:10/059,115
Patent Claims: 1. A method for preparing microparticles having a selected release profile for release of active agent contained in the microparticles, comprising: (a) dissolving a polymer in a solvent, and dissolving or dispersing the active agent in the solvent to form a discontinuous phase; (b) combining the discontinuous phase with a continuous phase to form an emulsion; (c) extracting at least a portion of the solvent from the emulsion to form microparticles containing the active agent; (d) selecting a degree of intermediate drying of the microparticles to be performed so that the selected release profile is achieved; and (e) final drying the microparticles.

2. The method of claim 1, wherein the selecting step (d) is carried out to select no intermediate drying, thereby resulting in microparticles having an initial burst and a substantially linear release profile.

3. The method of claim 1, wherein the selecting step (d) is carried out to select substantially compete intermediate drying, thereby resulting in microparticles having an initial lag phase and a substantially sigmoidal release profile.

4. The method of claim 3, further comprising after step (d) and prior to step (e): (f) performing the selected degree of intermediate drying.

5. The method of claim 4, wherein the substantially complete intermediate drying results in the microparticles having a moisture content of less than about 0.2% after step (f).

6. The method of claim 1, wherein extracting step (c) is carried out using a quench liquid.

7. The method of claim 1, wherein the combining step (b) is carried out using a static mixer.

8. The method of claim 1, wherein the solvent is a solvent blend.

9. The method of claim 8, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxyrisperidone, and pharmaceutically acceptable salts of the foregoing, and the solvent blend comprises ethyl acetate and benzyl alcohol.

10. A microencapsulated active agent having a selected release profile prepared by a method for preparing microparticles, the method comprising: (a) dissolving a polymer in a solvent, and dissolving or dispersing the active agent in the solvent to form a discontinuous phase; (b) combining the discontinuous phase with a continuous phase to form an emulsion; (c) extracting at least a portion of the solvent from the emulsion to form microparticles containing the active agent; (d) selecting a degree of intermediate drying of the microparticles to be performed so that the selected release profile is achieved; and (e) final drying the microparticles.

11. The microencapsulated active agent of claim 10, wherein the selecting step (d) is carried out to select no intermediate drying, thereby resulting in microparticles having an initial burst and a substantially linear release profile.

12. The micro encapsulated active agent of claim 10, wherein the selecting step (d) is carried out to select substantially complete intermediate drying, thereby resulting in microparticles having an initial lag phase and a substantially sigmoidal release profile.

13. The microencapsulated active agent of claim 10, wherein the method further comprises after step (d) and prior to step (e): (f) performing the selected degree of intermediate drying.

14. The microencapsulated active agent of claim 13, wherein the substantially complete intermediate drying results in the microparticles having a moisture content of less than about 0.2% after step (f).

15. The microencapsulated active agent of claim 10, wherein the solvent is a solvent blend.

16. The microencapsulated active agent of claim 15, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxyrisperidone, and pharmaceutically acceptable salts of the foregoing, and the solvent blend comprises ethyl acetate and benzyl alcohol.

17. Microparticles prepared by the method of claim 1.

18. The microparticles of claim 17, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxyrisperidone, and pharmaceutically acceptable salts of the foregoing.

19. The microparticles of claim 18, wherein the solvent is a solvent blend comprising ethyl acetate and benzyl alcohol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc